Vycor Medical, Inc. reported its financial results for the second quarter of 2025, revealing a revenue increase of 22% to $496,353 compared to $406,278 in the same period of 2024. For the first half of 2025, total revenue reached $932,731, up from $743,246 in the prior year, driven primarily by a 24% increase in sales from its Vycor Medical division, which generated $481,788 in the second quarter. The company reported a gross profit of $415,271 for the quarter, reflecting a gross margin of 83%, down from 91% in the previous year, attributed to validation and shipping costs associated with new production.
In terms of profitability, Vycor Medical achieved an operating income of $51,146 for the second quarter, a significant increase from $16,178 in the same quarter of 2024. The company’s net income for the quarter was $23,887, compared to a net loss of $10,038 in the prior year. However, for the six months ended June 30, 2025, Vycor reported a net loss of $14,676, an improvement from a loss of $40,646 in the same period of 2024. The company’s accumulated deficit increased to $33,428,921 as of June 30, 2025.
Operationally, Vycor Medical has focused on expanding its market presence, particularly in international markets, which contributed to the revenue growth. The company’s research and development expenses rose to $4,201 for the second quarter, reflecting ongoing efforts to develop new products. Selling, general, and administrative expenses also increased to $345,043, partly due to non-cash stock-based compensation related to a financial advisory agreement with Maxim Group LLC. The company’s total assets decreased to $878,946 from $998,117 at the end of 2024, primarily due to a reduction in current assets.
The company continues to face challenges, including a working capital deficiency of $4,027,184, which raises concerns about its ability to continue as a going concern. Vycor Medical has indicated that it may need to seek additional funding through debt or equity to meet its cash needs. The company is executing a plan to reduce cash operating losses and is exploring strategic partnerships and acquisitions to enhance growth. Despite the positive revenue trends, the ongoing financial challenges and the need for additional capital remain critical issues for the company moving forward.
About VYCOR MEDICAL INC
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.